# A Study to Compare Effectiveness and Safety of Darunavir/Ritonavir (DRV/Rtv) 800mg/100mg Once Daily Versus DRV/Rtv 600mg/100mg Twice Daily in Early Treatment-Experienced HIV-1 Infected Patients (ODIN)

> **NCT00524368** · PHASE3 · COMPLETED · sponsor: **Tibotec Pharmaceuticals, Ireland** · enrollment: 590 (actual)

## Conditions studied

- Human Immunodeficiency Virus - Type 1

## Interventions

- **DRUG:** Darunavir (DRV)
- **DRUG:** Ritonavir (rtv)

## Key facts

- **NCT ID:** NCT00524368
- **Lead sponsor:** Tibotec Pharmaceuticals, Ireland
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-10
- **Primary completion:** 2009-08
- **Final completion:** 2011-10
- **Target enrollment:** 590 (ACTUAL)
- **Last updated:** 2013-02-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00524368

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00524368, "A Study to Compare Effectiveness and Safety of Darunavir/Ritonavir (DRV/Rtv) 800mg/100mg Once Daily Versus DRV/Rtv 600mg/100mg Twice Daily in Early Treatment-Experienced HIV-1 Infected Patients (ODIN)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00524368. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*